# Cardinal Health (CAH) financials

Cardinal Health reported revenue of $254.2 billion for fiscal year 2026 (the twelve months to 30 Jun 2026), up 14.2% from fiscal 2025. Net income was $1.71 billion and diluted earnings per share $7.23.

In its latest reported quarter, the first quarter of fiscal 2027 (the three months to 30 Sep 2026), revenue was $67.5 billion, up 5.5% from a year earlier.

Source: Cardinal Health's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 5 Nov 2026. Amounts in USD. Page: https://aapwire.com/stocks/CAH. Retrieved 2026-11-16.

## Latest results: Q1 FY2027

Cardinal Health reported revenue of $67.5 billion, up 5.5% from a year earlier, net income of $554 million and diluted earnings per share of $2.38 against $1.88 for the first quarter of fiscal 2027 (the three months to 30 Sep 2026).

From its quarterly report, filed 5 Nov 2026.

| Measure | Q1 FY2027 | Q1 FY2026 | Change |
| --- | ---: | ---: | ---: |
| Revenue | $67.51B | $64.01B | +5.5% |
| Gross profit | $2.60B | $2.32B | +11.9% |
| Gross margin | 3.8% | 3.6% | +0.2 pts |
| Operating income | $753.0M | $668.0M | +12.7% |
| Operating margin | 1.1% | 1.0% | +0.1 pts |
| Net income | $554.0M | $450.0M | +23.1% |
| Diluted EPS | $2.38 | $1.88 | +26.6% |
| Operating cash flow | $1.40B | $973.0M | +43.7% |
| Capital expenditure | $157.0M | $108.0M | +45.4% |
| Free cash flow | $1.24B | $865.0M | +43.5% |

Page: https://aapwire.com/stocks/CAH/earnings

## Annual figures (fiscal years)

| Measure | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $130.0B | $136.8B | $145.5B | $152.9B | $162.5B | $181.3B | $205.0B | $226.8B | $222.6B | $254.2B |
| Revenue growth | +6.9% | +5.3% | +6.4% | +5.1% | +6.2% | +11.6% | +13.0% | +10.7% | −1.9% | +14.2% |
| Gross profit | $6.54B | $7.18B | $6.83B | $6.87B | $6.78B | $6.48B | $6.87B | $7.41B | $8.17B | $9.77B |
| Operating income | $2.12B | $126.0M | $2.06B | −$4.10B | $472.0M | −$607.0M | $752.0M | $1.24B | $2.27B | $2.61B |
| Net income | $1.29B | $256.0M | $1.36B | −$3.70B | $611.0M | −$938.0M | $330.0M | $852.0M | $1.56B | $1.71B |
| Diluted EPS | $4.03 | $0.81 | $4.53 | −$12.61 | $2.08 | −$3.37 | $1.26 | $3.45 | $6.45 | $7.23 |
| Operating cash flow | $1.18B | $2.77B | $2.72B | $1.96B | $2.43B | $3.17B | $2.84B | $3.76B | $2.40B | $5.17B |
| Capital expenditure | $387.0M | $384.0M | $328.0M | $375.0M | $400.0M | $387.0M | $481.0M | $511.0M | $547.0M | $649.0M |
| Free cash flow | $797.0M | $2.38B | $2.39B | $1.58B | $2.03B | $2.79B | $2.36B | $3.25B | $1.85B | $4.53B |
| Gross margin | 5.0% | 5.2% | 4.7% | 4.5% | 4.2% | 3.6% | 3.4% | 3.3% | 3.7% | 3.8% |
| Operating margin | 1.6% | 0.1% | 1.4% | −2.7% | 0.3% | −0.3% | 0.4% | 0.5% | 1.0% | 1.0% |
| Net margin | 1.0% | 0.2% | 0.9% | −2.4% | 0.4% | −0.5% | 0.2% | 0.4% | 0.7% | 0.7% |
| Cash and equivalents | $6.88B | $1.76B | $2.53B | $2.77B | $3.41B | $4.72B | $4.08B | $5.13B | $3.87B | $4.86B |
| Total debt | $11.25B | $9.01B | $8.03B | $7.25B | $6.68B | $5.79B | $5.17B | $5.62B | $9.35B | $9.95B |
| Shareholders' equity | $6.81B | $6.06B | $6.33B | $1.79B | $1.79B | −$709.0M | −$2.96B | −$3.21B | −$2.78B | −$2.88B |
| Diluted shares | 320M | 315M | 301M | 293M | 294M | 279M | 262M | 247M | 242M | 237M |
| Dividends per share | $1.80 | $1.85 | $1.91 | $1.92 | $1.94 | $1.96 | $1.98 | $2.00 | $2.02 | $2.04 |

## Quarterly figures (last eight fiscal quarters)

| Measure | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Q4 FY2026 | Q1 FY2027 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $55.26B | $54.88B | $60.16B | $64.01B | $65.63B | $60.94B | $63.67B | $67.51B |
| Revenue, year on year | −3.8% | 0.0% | +0.5% | +22.4% | +18.8% | +11.0% | +5.8% | +5.5% |
| Gross margin | 3.5% | 3.9% | 3.7% | 3.6% | 3.7% | 4.1% | 4.0% | 3.8% |
| Operating income | $549.0M | $730.0M | $428.0M | $668.0M | $707.0M | $509.0M | $729.0M | $753.0M |
| Net income | $400.0M | $506.0M | $239.0M | $450.0M | $467.0M | $399.0M | $398.0M | $554.0M |
| Diluted EPS | $1.65 | $2.10 | $1.00 | $1.88 | $1.97 | $1.69 | $1.70 | $2.38 |
| Free cash flow | −$495.0M | $2.79B | $1.29B | $865.0M | $555.0M | $1.68B | $1.43B | $1.24B |

## Operating KPIs

| KPI | Latest | Period | Change on a year |
| --- | ---: | --- | --- |
| [At-Home Solutions revenue](https://aapwire.com/stocks/CAH/kpi/at-home-solutions-revenue) | $1.1B | quarter to 30 Sep 2026 | up 2.8% |
| [Nuclear and Precision Health Solutions revenue](https://aapwire.com/stocks/CAH/kpi/nuclear-and-precision-health-solutions-revenue) | $505.0M | quarter to 30 Sep 2026 | up 15.8% |
| [Nuclear Precision Health Services revenue](https://aapwire.com/stocks/CAH/kpi/nuclear-precision-health-services-revenue) | $478.0M | quarter to 31 Mar 2026 | up 18.6% |
| [OptiFreight revenue](https://aapwire.com/stocks/CAH/kpi/optifreight-revenue) | $113.0M | quarter to 30 Sep 2026 | up 25.6% |
| [OptiFreight Logistics revenue](https://aapwire.com/stocks/CAH/kpi/optifreight-logistics-revenue) | $100.0M | quarter to 31 Mar 2026 | up 19.0% |
| [Pharmaceutical and Specialty Solutions revenue](https://aapwire.com/stocks/CAH/kpi/pharmaceutical-and-specialty-solutions-revenue) | $62.6B | quarter to 30 Sep 2026 | up 5.7% |
| [GMPD revenue](https://aapwire.com/stocks/CAH/kpi/gmpd-revenue) | $3.2B | quarter to 30 Sep 2026 | up 0.2% |

## Method

Each period is read from the report the company filed and checked against accounting identities; a figure that does not pass is left blank (—), never estimated. Free cash flow is operating cash flow less capital expenditure. Diluted EPS is as the company reported it, adjusted for later stock splits. Research information only, not investment advice.
